The Cancer Institute of New Jersey's physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life.
The Cancer Institute of New Jersey is a matrix style, basic, clinical and population research center as well as a consortium cancer center with Rutgers University and Princeton University leveraging the science of the state's cancer researchers through collaboration. CINJ is sharply focused on fulfilling the cancer research needs of the most densely populated and industry rich state in the nation.
The Cancer Institute of New Jersey research programs and core facilities enhance and support the cancer research of more than 160 members at Rutgers University, UMDNJ-Robert Wood Johnson Medical School, UMDNJ-School of Public Health and UMDNJ-New Jersey Medical School, as well as Princeton University and the Institute for Advanced Study in Princeton.
Research is currently being conducted in areas including: population science, systems biology, oncogenesis, tumor virology and immunology, autophagy, drug development and resistance, the relationship between cellular and genetic alterations and tumor development, cancer control and prevention, bioinformatics, and cancer genomics.
CINJ continues to expand its foundation of knowledge and the technical tools with which rapid advances can be made in understanding the mechanisms of cancer. Opportunities to manage the disease have increased and clinical research studies have yielded results that will have a profound effect in the prevention and treatment of many cancers.